Objective Liquid biopsies are being rapidly used in adult cancers as new biomarkers of disease. Circulating tumor DNA (ctDNA) levels have been reported to be proportional to disease burden, correlate with treatment response, and predict relapse. However, little is known about how frequently ctDNA is detectable in pediatric patients with solid tumors. Therefore, we developed a next-generation sequencing approach to detect and quantify ctDNA in the blood of patients with the most common pediatric solid tumors.
INTRODUCTION
Cancer remains one of the most common childhood causes of disease-related death in developed countries. 1 Patients with pediatric solid tumor malignancies are commonly treated with regimens that combine intensive chemotherapy, surgery, and radiation therapy. 2 This approach has led to tremendous improvements in outcome, with overall cure rates for pediatric solid tumors now > 80%. 3 However, these cures come at the cost of exposing patients to a high risk of long-term toxicities resulting in significant morbidity. 4 In some diseases, such as Wilms tumor, efforts to de-escalate therapy have resulted in stable cure rates for low-risk patients accompanied by reduced treatment toxicity. 5, 6 In other diseases, such as Ewing sarcoma, a lack of prognostic biomarkers limit the ability to risk stratify therapy. 7, 8 In both cases, the development of new and more precise assays for risk stratification could improve outcomes by facilitating patient-specific treatment modifications.
Advances in the development of liquid biopsy assays provide a new opportunity for prognostication in cancer. Numerous studies have now demonstrated that circulating tumor DNA (ctDNA) levels in adults with cancer correlate with disease burden and track with treatment responses over time. [9] [10] [11] [12] [13] [14] The development of ctDNA assays rely on identification and quantification of somatic mutations. 9, 15 Many ctDNA assays have been developed to detect highly recurrent hot-spot mutations that frequently drive adult malignancies. 9, 12, 13, [16] [17] [18] However, recent comprehensive sequencing efforts in pediatric cancers show that pediatric solid tumors are rarely driven by highly recurrent single-nucleotide variants. 19 Instead, structural variants, including chromosomal copy number changes and DNA translocations, are common somatic events in these tumor types. [20] [21] [22] [23] [24] [25] [26] To determine whether patients with childhood solid tumor malignancies express detectable levels of ctDNA, we adapted two next-generation sequencing strategies to detect and quantify structural variants in the plasma of these patients. We applied these assays to five of the most common types of pediatric solid tumors, excluding CNS tumors, to quantify ctDNA levels, identify genomic subtypes, and confirm the feasibility of using ctDNA assays to track disease response to therapy.
METHODS

Patients and Tissue Samples
Patients at the Dana-Farber Cancer Institute and Boston Children's Hospital were consented to an institutional review board-approved protocol. Patients were included if an initial peripheral blood, pleural effusion, or bone marrow sample was collected within 3 days from the start of chemotherapy and before a surgical resection. A confirmed pathologic diagnosis of Ewing sarcoma, alveolar rhabdomyosarcoma, osteosarcoma, Wilms tumor, or neuroblastoma was required. Additional details are available in the Data Supplement.
Sequencing Library Preparation, Sequencing Alignment, and Ultralow Passage Whole-Genome Sequencing Coverage
For all experiments, sequencing library preparation and sequencing data alignment were performed using standard techniques. For ultralow passage whole-genome sequencing (ULP-WGS), whole-genome libraries were pooled and sequenced (without selection) to achieve an anticipated average coverage between 0.2× and 1×. Additional details are available in the Data Supplement.
Translocation-Specific Sarcoma Sequencing Assay Development and Sequencing
To detect pediatric sarcoma-specific translocations in cell-free DNA, we developed a unique hybrid capture sequencing assay. First, we reviewed the literature to identify the genomic introns involved in oncogenic translocations in the EWSR1, FUS, CIC, CCNB3, PAX3, PAX7, and TP53 genes. 20, 21, [25] [26] [27] [28] [29] [30] [31] [32] [33] Second, we used the SureSelect Advanced Design Wizard (Agilent Technologies, Santa Clara, CA) to create capture probes targeting these regions and the coding regions of TP53 and STAG2 with the following design options: sense strand, 3× tiling density, least stringent masking, balanced boosting, and region extensions of 10 bases from the 3′ and 5′ ends (Data Supplement). The resulting hybrid capture bait set was named Translocation-Specific Sarcoma Sequencing assay (TranSS-Seq). Normalized and pooled barcoded sequencing libraries were enriched using the SureSelect XT Fast Target Enrichment System (Agilent Technologies) and the TranSS-Seq bait set. Postenrichment captures were sequenced with an intended coverage at target regions of 500×. The average measured coverage at enrichment sites for all samples tested by TranSS-Seq was 655× (range, 31× to 1,464×).
Sequencing Analysis
ULP-WGS analysis was performed using the ichorCNA algorithm (https://github.com/broadinstitute/ichorCNA), with manual curation of results. 34 In brief, ULP-WGS uses relative sequencing coverage of whole-genome data and computational correction of sequencing bias to detect segmental copy number changes. Percentage of ctDNA was determined using established probabilistic modeling algorithms for estimating tumor allelic fractions.
Identification of targeted translocations by
TranSS-Seq was performed using BreaKmer. 35 To quantify the number of translocations and wild-type reads detected in each sample, we developed a custom algorithm designed to realign all sequencing reads to either the reference human genome or the patient-specific translocationpositive reference sequence (https://github.com/ vanallenlab/peds_ctDNA). The algorithm then reported the number of reads aligned at the patient-specific translocation breakpoint and the number of wild-type reads at the equivalent genomic base-pair location within the human reference genome. Because each cancer genome contains one translocated and one wild-type allele, whereas germline genomes contain two wild-type alleles, we used the following formula to calculate the percentage of ctDNA, where T equals the number of translocation reads and W equals the number of wild-type reads:
Cell Lines and Digital Droplet Polymerase Chain Reaction
The EW8 Ewing sarcoma cell line dilution experiments, digital droplet polymerase chain reaction (ddPCR) methods, and ddPCR primers are listed in the Data Supplement.
RESULTS
Patients and Samples
A liquid biopsy sample was collected before the initiation of therapy from 45 pediatric patients with cancer with a confirmed diagnosis of Ewing sarcoma (n = 11), osteosarcoma (n = 10), neuroblastoma (n = 10), Wilms tumor (n = 8), or alveolar rhabdomyosarcoma (n = 7). Clinical characteristics were collected for each enrolled patient (Data Supplement). DNA from a tumor biopsy sample was available for eight of 11 Ewing sarcomas, four of 10 osteosarcomas, and six of seven rhabdomyosarcomas. DNA from tumor biopsy material from patients with neuroblastoma and Wilms tumor were not readily available.
Circulating Tumor DNA Is Detectable in Patients With Pediatric Solid Tumor Malignancies
Total cell-free DNA levels ranged from 2 ng to 3.5 µg of DNA per 1 mL of plasma, with the highest values originating from patients with neuroblastoma ( Fig 1A) . ULP-WGS was performed for each sample to detect and quantify ctDNA by measuring segmental copy number changes as recently described. 34 ctDNA was detected in ≥ 50% of pretreatment plasma samples from patients with osteosarcoma, neuroblastoma, Wilms tumor, and alveolar rhabdomyosarcoma. ctDNA was detected in only four of 11 samples from patients with Ewing sarcoma ( Fig 1B; Data Supplement). ULP-WGS was performed for all patients with available DNA from tumor biopsies (n = 18). In patients with detectable ctDNA, the pattern of segmental chromosomal copy number changes in cellfree DNA matched the copy number pattern observed in the tumor biopsy from the same patient (Figs 1C and 1D; Data Supplement). In four of the seven patients with Ewing sarcoma with no detectable ctDNA, ULP-WGS analysis of tumor biopsy DNA material demonstrated no discernable segmental copy number changes ( Fig 2) . This finding is consistent with previous reports that Ewing sarcoma tumors have few highly recurrent somatic events other than the EWSR1/ETS translocations and suggests that an alternative method for detection of ctDNA is necessary for this disease. 21, 26 
Translocation Detection Outperforms Copy Number Detection for Ewing Sarcoma
To detect ctDNA in translocation-positive tumors, we developed a novel hybrid-capture assay, termed TranSS-Seq, designed to sequence intronic regions involved in genomic rearrangements in pediatric sarcomas. Coding regions of the TP53 and STAG2 genes were also targeted by this assay (Table 1 ; Data Supplement). First, we confirmed that the assay could detect the expected translocations in a panel of Ewing and Ewing-like sarcomas and alveolar rhabdomyosarcomas (Data Supplement). Second, DNA was extracted from the EW8 Ewing sarcoma cell line and mixed in decreasing concentrations with normal human cell line CEPH-1347-2. ddPCR in these samples confirmed the ability to detect and quantify the EW8-specific EWSR1/FLI translocation across the range of dilutions ( Fig  3A; Data Supplement). Sequencing of the same DNA libraries with TranSS-Seq demonstrated a high correlation for this method with both the experimental dilution and ddPCR results and detected EW8 DNA at a concentration of 1.56% (Figs 3B and 3C; Data Supplement).
TranSS-Seq was then applied to cell-free DNA samples from patients with Ewing sarcoma and alveolar rhabdomyosarcoma. ctDNA was detected by this method in 10 of 11 Ewing sarcoma samples and five of seven alveolar rhabdomyosarcoma samples ( Fig 3D) . For five patients with Ewing sarcoma and three patients with alveolar rhabdomyosarcoma, DNA from tumor biopsy samples was also profiled by TranSS-Seq (Data Supplement). In all cases, the unique genomic breakpoint in the ctDNA was identical to the breakpoint observed from the tumor biopsy sample.
Previous studies in Ewing sarcoma have used ddPCR assays that amplify patient-specific EWS/ ETS translocations to measure ctDNA levels in patients. [36] [37] [38] To compare TranSS-Seq with this previously validated approach, patientspecific polymerase chain reaction primers were developed for a subset of Ewing sarcoma and alveolar rhabdomyosarcoma samples (Data Supplement). The percentage of ctDNA levels identified by TranSS-Seq correlated with the percentage of ctDNA detected by ddPCR ( copy number change but ULP-WGS was unable to detect ctDNA from the same patient (MRD0019, MRD0023, MRD0046), TranSS-Seq detected low levels of ctDNA, suggesting that TranSS-Seq may have greater sensitivity for ctDNA than ULP-WGS in Ewing sarcoma (Data Supplement).
ctDNA Levels Track With Disease Burden in Pediatric Solid Tumors
When comparing ctDNA levels across cancer types, neuroblastoma demonstrated a significantly higher percentage of ctDNA (median, 55%; range, 13% to 98%) than other cancer types (Data Supplement). This may reflect the high disease burden typically present in patients with metastatic neuroblastoma. For a subset of patients, liquid biopsy samples were collected at multiple time points during clinical care (Data Supplement). ULP-WGS was applied to all serial samples, and TranSS-Seq was applied to Ewing sarcoma and alveolar rhabdomyosarcoma samples. Changes in ctDNA levels over time corresponded to response to therapy (Fig 4; Data Supplement). In patients with newly diagnosed Ewing sarcoma and alveolar rhabdomyosarcoma, ctDNA levels declined rapidly after initiation of chemotherapy, often becoming undetectable by the start of the second cycle (Figs 4A and 4B; Data Supplement). In osteosarcoma, studies have shown that a high percentage of tumor necrosis observed in the primary tumor after neoadjuvant chemotherapy is associated with a better prognosis. 39, 40 In five patients with newly diagnosed osteosarcoma, the percentage of tumor necrosis was available. Interestingly, for one patient with tumor necrosis of 90% (MRD0061) and one patient with 80% (MRD0053), ctDNA levels were undetectable after initiation of chemotherapy ( Fig 4C; Data Supplement). However, four patients with tumor necrosis < 70% (MRD0031, MRD0036, MRD0040, MRD0054) had detectable ctDNA in at least one sample collected after initiation of chemotherapy ( Fig 4D; Data Supplement) . Finally, in patients whose ctDNA levels became undetectable with therapy but then experienced a clinical relapse or progression, ctDNA was again detectable before the initiation of relapsed therapy ( Fig 4B; Data Supplement) .
Genomic Markers of Poor Outcome Are Detectable in ctDNA
We also examined whether disease-specific genomic markers of prognosis could be detected in ctDNA. Recent studies demonstrate that mutations in STAG2 and TP53 may be associated with a worse outcome in Ewing sarcoma. 21, 26 A frame-shift mutation in STAG2 was detected by ctDNA from one patient (MRD0023), and a mutation in TP53 was detected in another patient (MRD0003; Data Supplement). In alveolar rhabdomyosarcoma, studies have demonstrated that patients with PAX3/FOXO1 have a worse prognosis than patients with PAX7/ FOXO1 translocation. 41 The FOXO1 fluorescent in situ hybridization probe, which is used in the diagnostic work-up of alveolar rhabdomyosarcoma, confirms a FOXO1 rearrangement but not the fusion partner. The TranSS-Seq assay distinguishes PAX3 from PAX7 translocations ( Table 1) . In our study, all patients with ctDNA were found to have a PAX3/FOXO1 translocation (Data Supplement). In osteosarcoma, copy number gains of chromosome arm 8q are associated with a poor outcome. [42] [43] [44] ULP-WGS detected copy number gains in 8q in seven of nine osteosarcoma samples with detectable ctDNA (Fig 1C; Data Supplement). Amplification of MYCN is a well-established marker of poor prognosis in neuroblastoma. 45, 46 MYCN amplification was detectable in the ctDNA of two patients by ULP-WGS ( Fig 5A; Data Supplement) . These were the only two patients with neuroblastoma with fluorescent in situ hybridization-confirmed MYCN amplification in our cohort. Finally, in Wilms tumor, copy number gains of 1q were associated with poor prognosis in favorable histology tumors. 47 ULP-WGS detected 1q gain in 6 ascopubs.org/journal/po JCO™ Precision Oncology 
DISCUSSION
Liquid biopsy technologies are currently being adapted for prognostic purposes in many adult malignancies. 11, [48] [49] [50] It is critical that liquid biopsy strategies are also developed for childhood cancer. Because of the relative rarity of pediatric solid tumors, large prospective trials frequently rely on multi-institutional consortiums to reach adequate patient enrollment. In this setting, availability of tumor biopsy samples for correlative biology studies is inconsistent. In addition, it is preferable to have a liquid biopsy approach that can provide information about disease burden and prognosis before availability of molecular results from tumor. Therefore, we adapted liquid biopsy methods that could detect somatic structural variants without requiring access to tumor biopsy samples. In this article, we report our results from profiling cell-free DNA samples from 45 patients diagnosed with a wide range of pediatric solid tumors.
We first applied ULP-WGS to detect copy number changes in cell-free DNA and found that the majority of patients with pediatric solid tumors ascopubs.org/journal/po JCO™ Precision Oncology 7 had detectable levels of ctDNA. Patients with neuroblastoma had the highest levels of ctDNA, including two patients with > 1 µg of cell-free DNA per mL of plasma, which was nearly 100% composed of tumor DNA. However, one obvious limitation to the use of ULP-WGS was in tumor types with low rates of copy number alterations, such as Ewing sarcoma.
Recent liquid biopsy studies in Ewing sarcoma have used the development of patient-specific ddPCR assays. [36] [37] [38] Although this approach has proven to be highly sensitive and quantitative, the development of each assay requires genomic profiling of large amounts of tumor biopsy material to establish the patient-specific oncogenic translocation. One recent study used a combination of ddPCR and hybrid capture sequencing to detect EWSR1 translocations in Ewing sarcoma and desmoplastic small roundcell tumors. 38 Results showed that it is feasible to detect EWSR1 translocations directly from the plasma of these patients without first sequencing the tumor sample. In our study, we developed a unique hybrid capture sequencing assay that targets a wider range of oncogenic translocations observed in pediatric sarcomas. Despite the larger genomic region targeted for hybrid capture, the TranSS-Seq assay detected ctDNA in 10 of 11 pretreatment samples obtained from Ewing sarcoma, similar to rates observed by other groups. Serial dilution studies demonstrated that our assay was sufficiently sensitive to detect oncogenic translocations diluted in germline DNA to as little as 1.56%. We also demonstrated that quantification of ctDNA levels was similar using either TranSS-Seq or ddPCR.
In this study, changes in ctDNA levels were observed during a patient's clinical course and corresponded to changes in disease burden. This suggests that next-generation sequencing approaches could be used as a measure of disease burden in patients before the start of therapy and to track treatment response. Monitoring changes in ctDNA levels during therapy may facilitate new response-based risk-stratification approaches that allow refinement of treatment intensity for patients undergoing therapy. With next-generation sequencing becoming increasingly available for clinical decision making, we anticipate that our ctDNA assays could also be adapted to clinical laboratory testing if they demonstrate significant improvements to risk stratification for pediatric solid tumors. A similar approach to risk-stratified treatment by minimal residual disease testing in children with acute lymphoblastic leukemia has led to significant improvements in outcome. 51 We believe that this study demonstrates the feasibility of measuring and tracking ctDNA across a wide range of pediatric solid tumors and justifies prospective efforts within each disease type to validate the use of ctDNA in prognostication. Importantly, our study was not optimized to determine which time points during a patient's treatment course may be the most useful in measuring response to therapy. Therefore, prospective studies should be designed to obtain frequent samples throughout treatment so that the time points most predictive of outcome can be appropriately identified.
Finally, our study demonstrates that nextgeneration sequencing of ctDNA can detect existing genomic biomarkers of outcome and may provide another modality for genomic profiling of tumors in patients. Furthermore, it remains unclear whether these genomic biomarkers are primarily clonal or heterogeneous events within a tumor or across tumors and whether the clonality of these genomic events changes in patients who relapse after therapy. Recent studies demonstrate that ctDNA can detect intratumor and multitumor heterogeneity and detect complex patterns of treatment resistance. [52] [53] [54] [55] With the emergence of new sequencing modifications that improve sensitivity and decrease sequencing errors, we believe that ctDNA profiling by next-generation sequencing approaches will improve our understanding of tumor heterogeneity and patterns of somatic evolution in pediatric solid tumors. 12, 16 In addition, the assays described in this study could facilitate broader profiling of ctDNA, such as deep whole-exome sequencing, by providing a mechanism to screen samples for the presence of sufficiently abundant ctDNA, allowing selection of samples most likely to yield informative data.
In summary, our study demonstrates that patients with pediatric solid tumors have detectable levels of ctDNA, which can be measured with nextgeneration sequencing approaches that do not require profiling of tumor biopsy material or patient-specific assays. Disease-specific genomic hallmarks of pediatric solid tumors can also be identified in liquid biopsy samples, and ctDNA levels correlate with disease burden and response to therapy over time. Larger studies are needed to confirm the prognostic value of ctDNA detection and quantification in these patients. As more sensitive and less error-prone sequencing technologies become available, we believe that ctDNA studies may provide insight into tumor evolution and treatment resistance in pediatric solid tumors. 
